Horizon Scores In Second Round Of Sjögren’s Trial A Month After Amgen Buyout
The company announced positive results in the second population of its Phase II study of dazodalibep in patients with Sj
You may also be interested in...
The US major has announced its biggest acquisition to date in the form of a takeover that should expand its rare disease franchise and stave off concerns about internal products facing biosimilar competition.
A Phase II trial of the anti-CD40 drug, which Horizon Therapeutics acquired in early 2021, met its primary endpoint in Sj
Horizon will gain the commercial product Uplizna and three pipeline products for rare diseases, where it can build on its success with Tepezza. Horizon is also interested in Viela's R&D team.